Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 31:12:1111-1128.
doi: 10.2147/JHC.S523806. eCollection 2025.

Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning

Affiliations

Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning

Fan Yao et al. J Hepatocell Carcinoma. .

Abstract

Purpose: To establish prediction models using Shapley Additive exPlanations (SHAP) and multiple machine learning (ML) algorithms to identify clinical features influencing hepatic arterial infusion chemotherapy (HAIC) resistance and survival in patients with hepatocellular carcinoma (HCC).

Patients and methods: We recruited 286 patients with unresectable HCC who underwent HAIC. Patients were divided into training and validation datasets (7:3 ratio). eXtreme Gradient Boosting (XGBoost) was used to build the preliminary resistance prediction model. The SHAP values explained the importance of the clinical features. Recursive Feature Elimination with Cross-Validation (RFECV) was used to select the optimum number of features. Seven ML methods were used to construct further resistance prediction models, and ten ML algorithms were employed to establish the survival prognosis models.

Results: The areas under the curve (AUC) of the XGBoost model were 1.000 and 0.812 for the training and validation groups, respectively. SHAP identified 27 of the 38 clinical features affecting resistance, with pre-HAIC treatment being the main factor. RFECV showed the best model performance with six features (pre-HAIC treatment, tumor size, HBV DNA, alkaline phosphatase (AKP), prothrombin time (PT), and portal vein tumor thrombosis (PVTT)). Random Forest had the best performance among the seven ML algorithms (AUC=0.935 for training, AUC=0.876 for validation). The combination of Stepcox [forward] and Gradient Boosting Machine was the best for predicting survival (AUC=0.98 in training, AUC=0.83 in validation). Based on the above clinical characteristics, patients were categorized into high-risk and low-risk groups based on the median risk score, and it was found that these characteristics also performed well in the prognostic model for predicting the survival of patients with HCC.

Conclusion: Pre-HAIC treatment, tumor size, HBV DNA, AKP, PT, and PVTT are effective predictors of post-HAIC resistance and survival in patients with unresectable advanced HCC.

Keywords: hepatocellular carcinoma outcomes; interpretable AI; prognostic modeling; treatment response prediction.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

None
Graphical abstract
Figure 1
Figure 1
The ROC curves of the prediction model based on XGBoost and logistic regression (without feature selection).
Figure 2
Figure 2
SHAP explanation based on XGBoost.
Figure 3
Figure 3
The dependence plots of six variables based on SHAP values.
Figure 4
Figure 4
Clinical baseline feature selection and prediction model construction.
Figure 5
Figure 5
The C-index of 10 ML algorithms in training set (Dataset1), the validation set (Dataset2) and the whole cohort after cross-combining.
Figure 6
Figure 6
The C-index and K-M survival curve of Stepcox [forward]+GBM.
Figure 7
Figure 7
The forest plot of Cox univariate analysis.

Similar articles

References

    1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y - DOI - PMC - PubMed
    1. Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158(4):410–420. doi:10.1001/jamasurg.2022.7989 - DOI - PubMed
    1. Fan ST. Hepatocellular carcinoma--resection or transplant?. Nat Rev Gastroenterol Hepatol. 2012;9(12):732–737. doi:10.1038/nrgastro.2012.158 - DOI - PubMed
    1. Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133–1146. doi:10.1016/S0140-6736(23)00961-3 - DOI - PubMed
    1. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2 - DOI - PubMed

LinkOut - more resources